

Equities

16 February 2012 | 15 pages

India Equity Strategy

Rally Reality – 30% in 33 days

Equities

- **30% in 33 days! Seen it before?** — Actually Yes. This rally – 33 trading days so far, and currency adjusted - only makes the middle of the 5 big rallies in the last decade. It is however clearly a very impressive rally: leader in local currency (+20%) and currency adjusted terms (+30%) amongst large EM/DM markets, India's strongest USD rally vs. EMs, and more broad-based (i.e. mid/cap and Small cap participation) than the index's performance would suggest. All this is good (and past), so we look closer at the reality of this rally, and (more importantly) question how real it is.
- **The Reality of this Rally** — How does this rally stack up against the previous 5 rallies? It is a) more broad-based (relative mid-cap/small cap performance is second best) b) starting from a relatively higher valuation (1yr fwd PE: 12.6x – second highest; range:9x-16.5x) c) Outperformance is led by the usual sector suspects (Materials: 16%, Industrials:10%, Financials: 8% and as always d) has been led by strong foreign Inflows, though this time there has been aggressive domestic selling (almost 50% of foreign buying). Not enough to say its 'different this time', but there are differences.
- **Real? Will it Rally on?** — India's had a few false starts - (11/21 15%+ rallies have petered out. But the four that have lasted 100 days have generated a 48% median local currency return (55% averages) and volumes have gone up sharply (86%). So far, the domestics haven't even participated; equities worldwide continue to rally, and Citi's Global and EM strategist expect the equity rally to go on: +11% for global equities, +15-20% for EM, from here. Will India continue to lead the rally, or at least rally along?
- **Fundamentally, we believe India's fair value is now near** — The Indian market, at 18,154 on the Sensex is almost at our fundamental December 2012 target of 18,400. We are holding our target. We would continue to position our portfolio relatively aggressively and for risk (and stay away from defensives): see overshoot risks on the upside rather than the downside. But we believe the markets' move now prices in a quickly recovering economy/corporate sector; this will likely take time (3/4QFY13), and the market will likely wait for most 2012 for the economy to catch up.

Aditya Narain, CFA

 +91-22-6631-9879
 aditya.narain@citi.com

Jitender Tokas, CFA
 jitender.tokas@citi.com

Figure 1. Sensex Rallies



Source: Bloomberg

See Appendix A-1 for Analyst Certification, Important Disclosures and non-US research analyst disclosures.

Citi Investment Research & Analysis is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.


Rally Reality

30% in 33 days

India has led the big markets, by quite a margin


India has led the global equity market rally: up 30% in 33 days in USD terms, 20% in local currency terms, and tracked closely only by Brazil amongst the relatively large EM's. It's in part a bounce-back from a very poor 2011 (-38% in USD), but it is nonetheless a very strong bounce-back.

Figure 2. 2012 YTD Equity Market Performance (Local Currency)



Source: MSCI, Datastream

Figure 3. 2012 YTD Equity Market Performance (USD)



Source: MSCI, Datastream

It's an impressive rally, but only in the middle of the pack of 5 strong rallies in the last decade

So is this big rally India's best and shiniest over the last decade? Actually no. It is one of five (which went all the 100-day way), and even amongst these rallies, it only lies in the middle of the pack, at an equivalent stage. The 2009 rally takes the lead – by a wide margin, and the 2005 rally (after a fall post a change in Government) also leads in early performance, compared with Jan / Feb 2012.

Figure 4. Sensex Rallies




Source: Bloomberg

It's a stronger rally in USD terms.....but still not its best


This is a relatively stronger rally in USD terms, compared with the previous market runs – but here too, it is only the third best rally of the five that sustained and have lasted the 100 trading days. Clearly, India's equity markets are highly and positively correlated with the currency, albeit a little more closely correlated this time.

Figure 5. MSCI India Rallies (INR)



Source: MSCI, Datastream

Figure 6. MSCI India Rallies (USD)



Source: MSCI, Datastream


India led EM's in 2009 and lagged them in 2003 (the two big EM rallies)...in USD terms, it is ahead this time

India's performance relative to EM's (in local currency) has tended to be more middle of the road in the early part of the rally (local currency): with India underperforming EM's in the 2003 rally, and outperforming in the 2009 rallies (the two big EM rallies – the other two were a little more India-centric). Its USD based performance this time though is stronger than any of the other rallies in the early part; and that India went on to out-perform at the 100 day mark of these rallies suggests a very strong start.

India's starting valuations are at the higher end of previous rallies...


Will this outperformance continue? We believe the jury is still out. In 2003, India was sitting on very low valuations and high operating leverage at the start of rally. And in 2009, valuations were a lot lower and while India did face a financing crisis economic momentum was only mildly interrupted by the slow down. This time, while the market's start has been strong in absolute and relative terms; starting valuations are less compelling, and its economic outlook more tepid.

Figure 7. MSCI India rel. to MSCI GEMs in rallies (local currency)



Source: MSCI, Datastream

Figure 8. . MSCI India rel. to MSCI GEMs in rallies (USD)




Source: MSCI, Datastream

...small and mid-caps are doing better than in 4/5 previous rallies

This is a broad market rally


This rally so far; is the second broadest of the five big ones that we consider; with the Mid and Small Caps recoding the second strongest performance relative to the narrower Sensex. While both lag the breadth of the 2003 rally, it is a broader rally relative to the 2009 one – which as rallies go, was clearly the sharpest and straightest of them all. The rallies of the past do also suggest a bit of surge in the mid/small caps closer to the mid point of the 100 day period: will it come this time, given that their moves has been more trend-line than in previous cases?

Figure 9. BSE Mid-Cap rel. to Sensex in rallies



Source: Bloomberg

Figure 10. BSE Small-Cap rel. to Sensex in rallies



Source: Bloomberg

Rally leaders are not very different
...materials, industrials and financials

Leaders and laggards are pretty traditional

Are the leaders and laggards very different this time? Not really: it's the rate sensitives – Materials / Industrials/ Financials that drove the market. And it's the traditional defensives – Consumers, IT and healthcare that make up the rear. We believe if the rally is to continue, then it will largely be these sectors that will lead, although materials will potentially be a little less predictable given the increasingly varied global driver. We also expect Consumer discretionary to potentially outperform going forward given their relative rate sensitivity and make more of a mark compared to the material sector.

Figure 11. Sector Leaders and Laggards in rallies (returns relative to MSCI India)

	Leaders			Laggards		
2003	Industrials (16%)	Cons. Discretionary (13%)	Materials (12%)	Cons.Staples (-17%)	IT (-4%)	Utilities (-2%)
2005	Cons. Discretionary (8%)	Cons. Staples (6%)	Energy (3%)	Materials (-8%)	Healthcare (-4%)	Utilities (-4%)
2007	Utilities (101%)	Financials (22%)	Energy (17%)	IT (-59%)	Healthcare (-35%)	Cons. Discretionary (-35%)
2009	Materials (46%)	Financials (42%)	Industrials (33%)	Cons. Staples (-61%)	Healthcare (-34%)	Utilities (-29%)
2012	Materials (16%)	Industrial (10%)	Financials (8%)	Cons. Staples (-17%)	IT (-14%)	Healthcare (-12%)

Source: MSCI, Datastream

Previous rallies – over 100 days...have gone a lot higher than the current one

Its not a particularly low valuation rally

Starting low, and so can go higher? No. India has not started this rally at a relative low: its starting valuations are at the higher end of previous 'start of rally' levels. It is also distinctly higher than the big 2003/2009 rallies. This does suggest that the headroom is potentially less than in previous rallies: though the 100 day gains for most of the rallies suggest there is meaningful headroom for the rally to generate more market gain. But typically, the lower you start, the higher you have to go: India

though currently remains well off the 100 day valuation levels previous rallies have reached. 67 days to go.

Figure 12. Change in valuation (1-Yr Fwd Consensus P/E)100 Days into rallies

	Sensex Returns	Starting P/E	Ending P/E	% Change in multiple
2003	46%	8.96	12.09	35%
2005	31%	11.57	15.11	31%
2007	49%	16.52	21.79	32%
2009	93%	9.75	17.24	77%
2012	18%	12.62	14.53	15%

Source: Factset

Its foreigners who are driving this rally too.....but almost for the first time, domestics have been selling into the rally

It is foreign money

Who is driving this rally? Not surprisingly, it is foreign money that is dominating the market and the flows this time are second only to 2007, and meaningfully more than the 2003 and 2009 Equity rallies (starting valuations though are higher). What is however different this time is that DII flows have actually been negative – over 50% of foreign inflows, and clearly moderating ‘what could have been’ if domestic’s had participated like in the past. Will domestic selling continue – and thereby stall the rally? Or could it reverse (as most domestics are believed to have underperformed the market, and have increasingly got hurt as the market has gone higher): and the second leg of domestic buying drives the market higher? The jury is out on this – but this could potentially moderate the dependence on foreign flows to sustain the rally.

Figure 13. Rallies and flows

	33 Days into Rally				100 Days into Rally			
	Flows			Sensex return	Flows			Sensex Return
	FII	DMF	DII		FII	DMF	DII	
2003	483	15		14%	2,291	(53)		46%
2005	(117)	912		10%	4,454	1,568		31%
2007	7,469	30	(963)	25%	10,899	1,556	3,306	49%
2009	1,686	417	435	39%	9,201	1,475	2,219	93%
2012	4,062	(596)	(2,299)	18%				


Source: SEBI, Bloomberg

What have Interest rates got to do with it...little so far, but matters globally, so let's keep a watch

‘What if’ rates start rising?


Our Global Equity Strategist has highlighted that Global equity rallies have historically got a little nipped as interest rates have started to rise. This is not the case this time, rates remain relatively stable, and they expect the rally to continue (a further +11% from here, for the MSCI world). In India’s case, we do not find a concomitant rise in rates during the 5 rallies we analyzed. With the RBI adopting a decidedly dovish stance on interest rates, we do not see rates as a potential impediment to the current rally.

Figure 14. US 10 Yr Govt. Bond Yield during rallies



Source: Datastream

Figure 15. India 10 Yr Govt. Bond Yield during rallies




Source: Bloomberg

Volumes usually go up a long way in such market moves...similar this time, but potentially a long way to go

It always is a volume story

What do volumes tell us? That the market is trading much more aggressively, that market volume expansion is in line with previous strong rallies, and if it were to sustain, it will be good for our business. That it remains largely foreign inflow driven - with relatively little evidence of retail participation at this stage - suggests that it has yet to take on the breadth of previous rallies. If it gets there, then there is enough evidence to suggest the rally could go on for a while. If not, then the dependence on only foreign money will continue (which could potentially be challenging, given India's significant outperformance).

Figure 16. Change in India turnover (30 day ma) during rallies*



Source: Bloomberg

* Change is measured relative to turnover 1 week prior to rally beginning

Figure 17. India Turnover (USD Mn)

	1 Week Ago	33-days	100-days	chg (33-days into rally)	chg (100-days into rally)
2003	728	800	1,414	10%	94%
2005	1,593	1,427	2,326	-10%	46%
2007	4,206	5,036	7,454	20%	77%
2009	2,258	3,660	5,130	62%	127%
2012	2,356	3,198		36%	

Source: Bloomberg

Fair Value and Model Portfolio

The call has worked so far....time to swim along, or get swamped

We like this Rally, particularly given our Dec 2011 ([2012 Outlook: Structural Pain In, Cyclical Gain Not](#)) call that the Indian market offers upfront upsides – and a December 2012 Sensex target of 18,400. But such sharp, liquidity backed and ‘going with the flow’ kind of investor and inflow momentum can be a scary thing. It is hard to get off the rising wave, and stand up against it; in some measure because you can get swamped by it, and in part because – as a lot of the data in this note suggests -- such rallies can go on a long way.

Stay with the fundamental view....the market should be at 18,400 at Dec 12...the market has moved, time for the economy/corporate sector to catch up...

We do however choose to run some risk and at the market level, stick with what we believe is fair value for the Indian market. Which remains 18,400 for Dec2012, based on a March 13 PE multiple of 14X, a slight discount to the markets long term multiple of 15.5-16X. We recognize the market mood has changed, there is more capital that is available (and that is critical for a market / economy like India), and there is probably a little less caution with the corporate sector than two months ago. But not enough has changed on the ground in the broader economy, or the corporate sector. We argue that while the macro and the market have moved favorably – the economy/corporate sector have to play catch up, and deliver in earnings, investment, expansion and risk appetite.

... and that could take more time than the markets current mood suggests

In our view, that will take some time – the market will expect it to start showing up almost immediately, and our own sense is that this is still 2/3 quarters away (India is now a big economy: once it starts slowing – as is the case, will take more than a some policy and market action to reverse this slackening momentum in a hurry). Our sense is that the markets’ bounce will moderate as real changes take time to come through. And the market will stay around fair value till some of this starts coming.


Overshoot risks on the upside.....

Are the risks on the upside or the downside? Rallies can go on and on, but big moves often retrace sharply. Our view is that the overshoot risks lie on the upside rather than the downside: the market had got oversold, the economy had not slowed as much as was made out to be the case, there is a real monetary peaking that is happening (along with inflation falling), and there was just too much caution on the Governments inaction – some of which is being unwound now. This mix, to us suggests, barring any meaningful global event, that market risks lie on the upside rather than the downside. And fair value rests a little above where we currently sit – which is where the market should revert to in the event of an overshoot.

Keep the portfolio and stocks aggressive....cut Telecom to UW, Financials remain the biggest bet..

So what do we do with our portfolio: keep it aggressive, biased towards interest rates cyclicals, and stay away from the defensives. We make modest changes in our portfolio, cut our Telecom OW to an UW, moderate our UW on materials, and slightly raise our weighting in the capital goods sector. Financials continue to remain our biggest OW, followed by automobiles. We also introduce more stocks – add on more risk, though we refrain from going too far down the quality spectrum. India is now supposed to be technically in a bull market (20% gains from its low): just the time not to throw caution (or quality) to the winds.

Figure 18. Model Portfolio Sector UWs/ UWs



Source: Citi Investment Research and Analysis

Figure 19. Citi India Model Portfolio

	Price 16-Feb-12 (Rs)	YTD Perf. (%)	RIC	Rating	MSCI Wt (%)	Portfolio Wt (%)	OW/ UW/Rel. MSCI (bps)	FY13			
								PE (x)	EPS Growth (%)	PB (x)	ROE (%)
Automobiles and Components					7.43	9.5	207				
M&M	725.5	6.2%	MAHM.BO	2		2.5	O/W	16	4.0%	3.0	20.8%
Maruti	1357.2	47.5%	MRTI.BO	1		3.0	O/W	23	36.2%	2.4	11.0%
Tata Motors	275.9	54.7%	TAMO.BO	1		4.0	O/W	7	22.8%	2.1	37.9%
Banks & Diversified Financials					25.55	31.0	545				
AXIS Bank	1222.7	51.6%	AXBK.BO	1		5.0	O/W	11	14.4%	1.9	19.2%
IDFC	146.0	59.1%	IDFC.BO	1		1.5	O/W	12	11.8%	1.6	13.7%
HDFC Bank	526.2	23.2%	HDBK.BO	2		5.2	U/W	19	28.5%	3.4	19.4%
ICICI Bank	968.9	41.5%	ICBK.BO	1		6.0	O/W	15	21.0%	1.7	12.4%
State Bank of India	2349.1	45.0%	SBI.BO	1		3.5	O/W	10	30.2%	1.7	18.1%
Yes Bank	366.4	53.5%	YESB.BO	1		1.0	O/W	11	23.5%	2.2	23.3%
Kotak Mahindra	573.8	32.7%	KTKM.BO	2		1.0	U/W	19	23.8%	2.8	16.2%
MMFSL	707.2	16.7%	MMFS.BO	1		1.0	O/W	10	22.2%	2.0	22.5%
Bank of Baroda	863.3	30.6%	BOB.BO	2		0.7	O/W	6	18.2%	1.1	20.9%
Industrials & Capital Goods					6.06	7.0	94				
Larsen & Toubro	1447.1	45.4%	LART.BO	1		4.0	O/W	19	7.8%	3.1	17.2%
Adani Port & SEZ	147.7	22.5%	APSE.BO	1		1.0	O/W	15	44.2%	4.3	32.4%
Cummins	469.5	34.5%	CUMM.BO	1		1.0	O/W	20	18.7%	5.8	30.2%
IRB Infra	201.5	55.0%	IRBI.BO	1		1.0	O/W	11	14.8%	1.9	18.4%
Energy					11.10	9.5	-160				
Reliance Industries	812.2	17.2%	RELI.BO	1		7.0	U/W	13	2.9%	1.4	11.9%
Caim	390.7	24.6%	CAIL.BO	1		2.5	O/W	7	35.5%	1.3	20.5%
Consumer					8.78	6.0	-278				
ITC	203.9	1.3%	ITC.BO	1		3.0	U/W	22	17.8%	8.9	41.8%
United Spirits	676.5	37.7%	UNSP.BO	1		3.0	O/W	19	28.1%	1.7	9.6%
Materials					10.93	10.0	-93				
Coal India	321.0	6.7%	COAL.BO	1		1.0	U/W	14	2.1%	3.6	29.9%
Hindalco	154.7	33.6%	HALC.BO	1		3.0	O/W	11	0.6%	0.9	8.3%
Jindal Steel & Power	640.0	41.2%	JNSP.BO	1		2.0	O/W	12	25.1%	2.6	25.2%
Grasim	2836.4	13.1%	GRAS.BO	1		1.0	O/W	11	-1.5%	1.4	13.6%
JSW Steel	859.7	69.5%	JSTL.BO	1		3.0	O/W	10	111.9%	1.0	11.1%
Pharmaceuticals, Biotechnology, Agrochem					4.84	6.0	116				
Ranbaxy	449.2	10.8%	RANB.BO	1H		2.0	O/W	17	42.1%	1.7	21.0%
Dr Reddy	1620.4	2.7%	REDY.BO	1		2.5	O/W	16	36.6%	3.6	26.8%
Lupin	489.0	9.3%	LUPN.BO	1		1.5	O/W	17	31.5%	4.3	27.8%
Software & Services					16.68	14.5	-218				
Infosys Technologies	2903.4	5.0%	INFY.BO	2		7.0	U/W	17	14.4%	4.3	27.6%
Tata Consultancy Services	1226.0	5.6%	TCS.BO	2		2.5	U/W	18	20.1%	5.5	34.0%
Wipro	438.6	10.0%	WIPR.BO	1		2.5	O/W	16	21.5%	3.2	22.3%
HCL Technologies	474.6	22.2%	HCLT.BO	1		2.5	O/W	13	23.3%	2.8	24.2%
Telecom Services					2.47	1.5	-97				
Bharti Airtel	350.3	2.1%	BRTI.BO	1		1.5	M/W	17	67.1%	2.3	14.4%
Utilities					5.09	4.0	-109				
Tata Power	113.4	29.9%	TTPW.BO	2		2.0	O/W	27	3.7%	2.2	8.3%
Power Grid Corp	110.6	10.7%	PGRD.BO	1		2.0	O/W	14	16.8%	2.0	14.4%
Real Estate					1.07	1.0	-7				
DLF	249.5	36.3%	DLF.BO	1		0.5	U/W	23	38.3%	1.6	7.1%
Phoenix	210.9	27.6%	PHOE.BO	1		0.5	O/W	21	21.5%	1.6	8.0%
Total					100.0	100.0					

Source: Citi Investment Research and Analysis

*Weights may not add up to 100 due to regulatory restrictions

Appendix A-1

Analyst Certification

The research analyst(s) primarily responsible for the preparation and content of this research report are named in bold text in the author block at the front of the product except for those sections where an analyst's name appears in bold alongside content which is attributable to that analyst. Each of these analyst(s) certify, with respect to the section(s) of the report for which they are responsible, that the views expressed therein accurately reflect their personal views about each issuer and security referenced and were prepared in an independent manner, including with respect to Citigroup Global Markets Inc and its affiliates. No part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) expressed by that research analyst in this report.

IMPORTANT DISCLOSURES

Citigroup Global Markets Inc. or its affiliates beneficially owns 1% or more of any class of common equity securities of Cummins India, HCL Technologies, IRB Infrastructure Developers, JSW Steel, Larsen & Toubro, Mahindra And Mahindra Financial Services, Maruti Suzuki India, Phoenix Mills, Ranbaxy, Dr Reddy, Tata Motors, Yes Bank. This position reflects information available as of the prior business day.

Within the past 12 months, Citigroup Global Markets Inc. or its affiliates has acted as manager or co-manager of an offering of securities of Bank of Baroda, ICICI Bank, Larsen & Toubro, Mahindra & Mahindra, Mahindra And Mahindra Financial Services, Power Grid Corporation of India, Reliance Industries, State Bank of India, Tata Motors, Tata Consultancy Services.

Citigroup Global Markets Inc. or its affiliates has received compensation for investment banking services provided within the past 12 months from AXIS Bank, Bank of Baroda, Cairn India, Coal India, Hindalco Industries, HDFC Bank, ICICI Bank, Infrastructure Development Finance, Jindal Steel and Power, Kotak Mahindra Bank, Larsen & Toubro, Mahindra & Mahindra, Mahindra And Mahindra Financial Services, Power Grid Corporation of India, Dr Reddy, Reliance Industries, State Bank of India, Tata Motors, Tata Consultancy Services, United Spirits, Yes Bank.

Citigroup Global Markets Inc. or its affiliates expects to receive or intends to seek, within the next three months, compensation for investment banking services from AXIS Bank, Bank of Baroda, Cairn India, Coal India, Hindalco Industries, ICICI Bank, Power Grid Corporation of India, State Bank of India, Wipro.

Citigroup Global Markets Inc. or an affiliate received compensation for products and services other than investment banking services from Adani Port And Special Economic Zone, AXIS Bank, Bank of Baroda, Bharti Airtel, Cairn India, Coal India, Cummins India, DLF, Grasim Industries, Hindalco Industries, HCL Technologies, HDFC Bank, ICICI Bank, Infrastructure Development Finance, Infosys Ltd, ITC, Jindal Steel and Power, JSW Steel, Kotak Mahindra Bank, Larsen & Toubro, Lupin, Mahindra & Mahindra, Mahindra And Mahindra Financial Services, Maruti Suzuki India, Power Grid Corporation of India, Phoenix Mills, Ranbaxy, Dr Reddy, Reliance Industries, State Bank of India, Tata Motors, Tata Consultancy Services, Tata Power, United Spirits, Wipro, Yes Bank in the past 12 months.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following as investment banking client(s): JSW Steel, Cairn India, AXIS Bank, Bank of Baroda, Coal India, Hindalco Industries, HDFC Bank, ICICI Bank, Infrastructure Development Finance, Jindal Steel and Power, Kotak Mahindra Bank, Larsen & Toubro, Mahindra & Mahindra, Mahindra And Mahindra Financial Services, Power Grid Corporation of India, Dr Reddy, Reliance Industries, State Bank of India, Tata Motors, Tata Consultancy Services, United Spirits, Wipro, Yes Bank.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following as clients, and the services provided were non-investment-banking, securities-related: Adani Port And Special Economic Zone, AXIS Bank, Bank of Baroda, Bharti Airtel, Cairn India, Coal India, Cummins India, DLF, Grasim Industries, Hindalco Industries, HCL Technologies, HDFC Bank, ICICI Bank, Infrastructure Development Finance, Infosys Ltd, ITC, Jindal Steel and Power, JSW Steel, Kotak Mahindra Bank, Larsen & Toubro, Lupin, Mahindra & Mahindra, Mahindra And Mahindra Financial Services, Maruti Suzuki India, Power Grid Corporation of India, Phoenix Mills, Ranbaxy, Dr Reddy, Reliance Industries, State Bank of India, Tata Motors, Tata Consultancy Services, Tata Power, Wipro, Yes Bank.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following as clients, and the services provided were non-investment-banking, non-securities-related: Adani Port And Special Economic Zone, AXIS Bank, Bank of Baroda, Bharti Airtel, Cairn India, Coal India, Cummins India, DLF, Grasim Industries, Hindalco Industries, HCL Technologies, HDFC Bank, ICICI Bank, Infrastructure Development Finance, Infosys Ltd, ITC, Jindal Steel and Power, JSW Steel, Kotak Mahindra Bank, Larsen & Toubro, Lupin, Mahindra & Mahindra, Mahindra And Mahindra Financial Services, Maruti Suzuki India, Power Grid Corporation of India, Ranbaxy, Dr Reddy, Reliance Industries, State Bank of India, Tata Motors, Tata Consultancy Services, Tata Power, United Spirits, Wipro, Yes Bank.

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability which includes investment banking revenues.

The Firm is a market maker in the publicly traded equity securities of Infosys Ltd.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citi Investment Research & Analysis product ("the Product"), please contact Citi Investment Research & Analysis, 388 Greenwich Street, 28th Floor, New York, NY, 10013, Attention: Legal/Compliance [E6WYB6412478]. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures. Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

Citi Investment Research & Analysis Ratings Distribution

12 Month Rating

Relative Rating

Data current as of 31 Dec 2011

	Buy	Hold	Sell	Buy	Hold	Sell
Citi Investment Research & Analysis Global Fundamental Coverage	57%	34%	9%	10%	79%	10%
% of companies in each rating category that are investment banking clients	45%	41%	40%	49%	43%	41%

Guide to Citi Investment Research & Analysis (CIRA) Fundamental Research Investment Ratings:

CIRA's stock recommendations include an investment rating and an optional risk rating to highlight high risk stocks.

Risk rating takes into account both price volatility and fundamental criteria. Stocks will either have no risk rating or a High risk rating assigned.

Investment Ratings: CIRA's investment ratings are Buy, Neutral and Sell. Our ratings are a function of analyst expectations of expected total return ("ETR") and risk. ETR is the sum of the forecast price appreciation (or depreciation) plus the dividend yield for a stock within the next 12 months. The Investment rating definitions are: Buy (1) ETR of 15% or more or 25% or more for High risk stocks; and Sell (3) for negative ETR. Any covered stock not assigned a Buy or a Sell is a Neutral (2). For stocks rated Neutral (2), if an analyst believes that there are insufficient valuation drivers and/or investment catalysts to derive a positive or negative investment view, they may elect with the approval of CIRA management not to assign a target price and, thus, not derive an ETR. Analysts may place covered stocks "Under Review" in response to exceptional circumstances (e.g. lack of information critical to the analyst's thesis) affecting the company and / or trading in the company's securities (e.g. trading suspension). As soon as practically possible, the analyst will publish a note re-establishing a rating and investment thesis. To satisfy regulatory requirements, we correspond Under Review and Neutral to Hold in our ratings distribution table for our 12-month fundamental rating system. However, we reiterate that we do not consider Under Review to be a recommendation.

Relative three-month ratings: CIRA may also assign a three-month relative call (or rating) to a stock to highlight expected out-performance (most preferred) or under-performance (least preferred) versus the geographic and industry sector over a 3 month period. The relative call may highlight a specific near-term catalyst or event impacting the company or the market that is anticipated to have a short-term price impact on the equity securities of the company. Absent any specific catalyst the analyst(s) will indicate the most and least preferred stocks in the universe of stocks under consideration, explaining the basis for this short-term view. This three-month view may be different from and does not affect a stock's fundamental equity rating, which reflects a longer-term total absolute return expectation. For purposes of NASD/NYSE ratings-distribution-disclosure rules, most preferred calls correspond to a buy recommendation and least preferred calls correspond to a sell recommendation. Any stock not assigned to a most preferred or least preferred call is considered non-relative-rated (NRR). For purposes of NASD/NYSE ratings-distribution-disclosure rules we correspond NRR to Hold in our ratings distribution table for our 3-month relative rating system. However, we reiterate that we do not consider NRR to be a recommendation.

Prior to October 8, 2011, the firm's stock recommendation system included a risk rating and an investment rating. **Risk ratings**, which took into account both price volatility and fundamental criteria, were: Low (L), Medium (M), High (H), and Speculative (S). **Investment Ratings** of Buy, Hold and Sell were a function of CIRA's expectation of total return (forecast price appreciation and dividend yield within the next 12 months) and risk rating. Additionally, analysts could have placed covered stocks "Under Review" in response to exceptional circumstances (e.g. lack of information critical to the analyst's thesis) affecting the company and/or trading in the company's securities (e.g. trading suspension). Stocks placed "Under Review" were monitored daily by management and as practically possible, the analyst published a note re-establishing a rating and investment thesis. For securities in developed markets (US, UK, Europe, Japan, and Australia/New Zealand), investment ratings were: Buy (1) (expected total return of 10% or more for Low-Risk stocks, 15% or more for Medium-Risk stocks, 20% or more for High-Risk stocks, and 35% or more for Speculative stocks); Hold (2) (0%-10% for Low-Risk stocks, 0%-15% for Medium-Risk stocks, 0%-20% for High-Risk stocks, and 0%-35% for Speculative stocks); and Sell (3) (negative total return). For securities in emerging markets (Asia Pacific, Emerging Europe/Middle East/Africa, and Latin America), investment ratings were: Buy (1) (expected total return of 15% or more for Low-Risk stocks, 20% or more for Medium-Risk stocks, 30% or more for High-Risk stocks, and 40% or more for Speculative stocks); Hold (2) (5%-15% for Low-Risk stocks, 10%-20% for Medium-Risk stocks, 15%-30% for High-Risk stocks, and 20%-40% for Speculative stocks); and Sell (3) (5% or less for Low-Risk stocks, 10% or less for Medium-Risk stocks, 15% or less for High-Risk stocks, and 20% or less for Speculative stocks).

Investment ratings are determined by the ranges described above at the time of initiation of coverage, a change in investment and/or risk rating, or a change in target price (subject to limited management discretion). At other times, the expected total returns may fall outside of these ranges because of market price movements and/or other short-term volatility or trading patterns. Such interim deviations from specified ranges will be permitted but will become subject to review by Research Management. Your decision to buy or sell a security should be based upon your personal investment objectives and should be made only after evaluating the stock's expected performance and risk.

NON-US RESEARCH ANALYST DISCLOSURES

Non-US research analysts who have prepared this report (i.e., all research analysts listed below other than those identified as employed by Citigroup Global Markets Inc.) are not registered/qualified as research analysts with FINRA. Such research analysts may not be associated persons of the member organization and therefore may not be subject to the NYSE Rule 472 and NASD Rule 2711 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account. The legal entities employing the authors of this report are listed below:

Citigroup Global Markets India Private Limited	Aditya Narain, CFA; Jitender Tokas, CFA; Deepal Delivala; Manish Chowdhary, CFA; Gaurav Malhotra, CFA; Saurabh Handa; Raashi Chopra, CFA; Venkatesh Balasubramaniam; Surendra Goyal, CFA; Pradeep Mahtani; Jamshed Dadabhoj; Atul Tiwari, CFA; Prashant Nair, CFA
--	---

OTHER DISCLOSURES

Citigroup Global Markets Inc. and/or its affiliates has a significant financial interest in relation to AXIS Bank, Bank of Baroda, ICICI Bank, Infrastructure Development Finance, ITC, Mahindra And Mahindra Financial Services, Dr Reddy, Reliance Industries, State Bank of India, Tata Consultancy Services, Wipro. (For an explanation of the determination of significant financial interest, please refer to the policy for managing conflicts of interest which can be found at www.citigroupgeo.com.)

Citigroup Global Markets Inc. or its affiliates beneficially owns 2% or more of any class of common equity securities of Cummins India, IRB Infrastructure Developers, Mahindra And Mahindra Financial Services, Tata Motors, Yes Bank.

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the issuer(s) discussed in the Product. The Firm may engage in securities

transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citi Investment Research & Analysis (CIRA) does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of CIRA to provide research coverage of the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in the Product must take into account existing public information on such security or any registered prospectus.

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

Important Disclosures for Morgan Stanley Smith Barney LLC Customers: Morgan Stanley & Co. LLC (Morgan Stanley) research reports may be available about the companies that are the subject of this Citi Investment Research & Analysis (CIRA) research report. Ask your Financial Advisor or use smithbarney.com to view any available Morgan Stanley research reports in addition to CIRA research reports.

Important disclosure regarding the relationship between the companies that are the subject of this CIRA research report and Morgan Stanley Smith Barney LLC and its affiliates are available at the Morgan Stanley Smith Barney disclosure website at www.morganstanleysmithbarney.com/researchdisclosures. For Morgan Stanley and Citigroup Global Markets, Inc. specific disclosures, you may refer to www.morganstanley.com/researchdisclosures and https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures.

This CIRA research report has been reviewed and approved on behalf of Morgan Stanley Smith Barney LLC. This review and approval was conducted by the same person who reviewed this research report on behalf of CIRA. This could create a conflict of interest.

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by. The Product is made available in **Australia** through Citigroup Global Markets Australia Pty Ltd. (ABN 64 003 114 832 and AFSL No. 240992), participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. The Product is made available in **Brazil** by Citigroup Global Markets Brasil - CCTVM SA, which is regulated by CVM - Comissão de Valores Mobiliários, BACEN - Brazilian Central Bank, APIMEC - Associação dos Analistas e Profissionais de Investimento do Mercado de Capitais and ANBID - Associação Nacional dos Bancos de Investimento. Av. Paulista, 1111 - 11º andar - CEP. 01311920 - São Paulo - SP. If the Product is being made available in certain provinces of **Canada** by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. This product is available in **Chile** through Banchile Corredores de Bolsa S.A., an indirect subsidiary of Citigroup Inc., which is regulated by the Superintendencia de Valores y Seguros. Agustinas 975, piso 2, Santiago, Chile. The Product is made available in **France** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. 1-5 Rue Paul Cézanne, 8ème, Paris, France. The Product is distributed in **Germany** by Citigroup Global Markets Deutschland AG ("CGMD"), which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). CGMD, Reuterweg 16, 60323 Frankfurt am Main. Research which relates to "securities" (as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong)) is issued in **Hong Kong** by, or on behalf of, Citigroup Global Markets Asia Limited which takes full responsibility for its content. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Research is made available through Citibank, N.A., Hong Kong Branch, for its clients in Citi Private Bank, it is made available by Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citibank N.A. is regulated by the Hong Kong Monetary Authority. Please contact your Private Banker in Citibank N.A., Hong Kong, Branch if you have any queries on or any matters arising from or in connection with this document. The Product is made available in **India** by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. The Product is made available in **Indonesia** through PT Citigroup Securities Indonesia. 5/F, Citibank Tower, Bapindo Plaza, Jl. Jend. Sudirman Kav. 54-55, Jakarta 12190. Neither this Product nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesian residents except in compliance with applicable capital market laws and regulations. This Product is not an offer of securities in Indonesia. The securities referred to in this Product have not been registered with the Capital Market and Financial Institutions Supervisory Agency (BAPEPAM-LK) pursuant to relevant capital market laws and regulations, and may not be offered or sold within the territory of the Republic of Indonesia or to Indonesian citizens through a public offering or in circumstances which

constitute an offer within the meaning of the Indonesian capital market laws and regulations. The Product is made available in **Israel** through Citibank NA, regulated by the Bank of Israel and the Israeli Securities Authority. Citibank, N.A., Platinum Building, 21 Ha'arba'ah St, Tel Aviv, Israel. The Product is made available in **Italy** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. Via dei Mercanti, 12, Milan, 20121, Italy. The Product is made available in **Japan** by Citigroup Global Markets Japan Inc. ("CGMJ"), which is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Shin-Marunouchi Building, 1-5-1 Marunouchi, Chiyoda-ku, Tokyo 100-6520 Japan. If the Product was distributed by SMBC Nikko Securities Inc. it is being so distributed under license. In the event that an error is found in an CGMJ research report, a revised version will be posted on the Firm's Citi Velocity website. If you have questions regarding Citi Velocity, please call (81 3) 6270-3019 for help. The Product is made available in **Korea** by Citigroup Global Markets Korea Securities Ltd., which is regulated by the Financial Services Commission, the Financial Supervisory Service and the Korea Financial Investment Association (KOFIA). Citibank Building, 39 Da-dong, Jung-gu, Seoul 110-180, Korea. KOFIA makes available registration information of research analysts on its website. Please visit the following website if you wish to find KOFIA registration information on research analysts of Citigroup Global Markets Korea Securities Ltd. <http://dis.kofia.or.kr/fs/dis2/fundMgr/DISFundMgrAnalystPop.jsp?companyCd2=A03030&pageDiv=02>. The Product is made available in **Malaysia** by Citigroup Global Markets Malaysia Sdn Bhd (Company No. 460819-D) ("CGMM") to its clients and CGMM takes responsibility for its contents. CGMM is regulated by the Securities Commission of Malaysia. Please contact CGMM at Level 43 Menara Citibank, 165 Jalan Ampang, 50450 Kuala Lumpur, Malaysia in respect of any matters arising from, or in connection with, the Product. The Product is made available in **Mexico** by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, Integrante del Grupo Financiero Banamex ("Accival") which is a wholly owned subsidiary of Citigroup Inc. and is regulated by Comision Nacional Bancaria y de Valores. Reforma 398, Col. Juarez, 06600 Mexico, D.F. In **New Zealand** the Product is made available to 'wholesale clients' only as defined by s5C(1) of the Financial Advisers Act 2008 ('FAA') through Citigroup Global Markets Australia Pty Ltd (ABN 64 003 114 832 and AFSL No. 240992), an overseas financial adviser as defined by the FAA, participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in **Pakistan** by Citibank N.A. Pakistan branch, which is regulated by the State Bank of Pakistan and Securities Exchange Commission, Pakistan. AWT Plaza, 1.1. Chundrigar Road, P.O. Box 4889, Karachi-74200. The Product is made available in the **Philippines** through Citicorp Financial Services and Insurance Brokerage Philippines, Inc., which is regulated by the Philippines Securities and Exchange Commission. 20th Floor Citibank Square Bldg. The Product is made available in the Philippines through Citibank NA Philippines branch, Citibank Tower, 8741 Paseo De Roxas, Makati City, Manila. Citibank NA Philippines NA is regulated by The Bangko Sentral ng Pilipinas. The Product is made available in **Poland** by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Nadzoru Finansowego. Dom Maklerski Banku Handlowego S.A. ul.Senatorska 16, 00-923 Warszawa. The Product is made available in the **Russian Federation** through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in **Singapore** through Citigroup Global Markets Singapore Pte. Ltd. ("CGMSPL"), a capital markets services license holder, and regulated by Monetary Authority of Singapore. Please contact CGMSPL at 1 Temasek Avenue, #39-02 Millenia Tower, Singapore 039192, in respect of any matters arising from, or in connection with, the analysis of this document. This report is intended for recipients who are accredited, expert and institutional investors as defined under the Securities and Futures Act (Cap. 289). The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore Branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Please contact your Private Banker in Citibank N.A., Singapore Branch if you have any queries on or any matters arising from or in connection with this document. This report is intended for recipients who are accredited, expert and institutional investors as defined under the Securities and Futures Act (Cap. 289). This report is distributed in Singapore by Citibank Singapore Ltd ("CSL") to selected Citigold/Citigold Private Clients. CSL provides no independent research or analysis of the substance or in preparation of this report. Please contact your Citigold/Citigold Private Client Relationship Manager in CSL if you have any queries on or any matters arising from or in connection with this report. This report is intended for recipients who are accredited investors as defined under the Securities and Futures Act (Cap. 289). Citigroup Global Markets (Pty) Ltd. is incorporated in the **Republic of South Africa** (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in **Spain** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. 29 Jose Ortega Y Gassef, 4th Floor, Madrid, 28006, Spain. The Product is made available in the **Republic of China** through Citigroup Global Markets Taiwan Securities Company Ltd. ("CGMTS"), 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan and/or through Citibank Securities (Taiwan) Company Limited ("CSTL"), 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan, subject to the respective license scope of each entity and the applicable laws and regulations in the Republic of China. CGMTS and CSTL are both regulated by the Securities and Futures Bureau of the Financial Supervisory Commission of Taiwan, the Republic of China. No portion of the Product may be reproduced or quoted in the Republic of China by the press or any third parties [without the written authorization of CGMTS and CSTL]. If the Product covers securities which are not allowed to be offered or traded in the Republic of China, neither the Product nor any information contained in the Product shall be considered as advertising the securities or making recommendation of the securities in the Republic of China. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security or financial products. Any decision to purchase securities or financial products mentioned in the Product must take into account existing public information on such security or the financial products or any registered prospectus. The Product is made available in **Thailand** through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F, 22/F and 29/F, 82 North Sathorn Road, Silom, Bangrak, Bangkok 10500, Thailand. The Product is made available in **Turkey** through Citibank AS which is regulated by Capital Markets Board. Tekfen Tower, Eski Buyukdere Caddesi # 209 Kat 2B, 23294 Levent, Istanbul, Turkey. In the **U.A.E.**, these materials (the "Materials") are communicated by Citigroup Global Markets Limited, DIFC branch ("CGML"), an entity registered in the Dubai International Financial Center ("DIFC") and licensed and regulated by the Dubai Financial Services Authority ("DFSA") to Professional Clients and Market Counterparties only and should not be relied upon or distributed to Retail Clients. A distribution of the different CIRA ratings distribution, in percentage terms for Investments in each sector covered is made available on request. Financial products and/or services to which the Materials relate will only be made available to Professional Clients and Market Counterparties. The Product is made available in **United Kingdom** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. This material may relate to investments or services of a person outside of the UK or to other matters which are not regulated by

the FSA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in **United States** by Citigroup Global Markets Inc, which is a member of FINRA and registered with the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is regulated by Financial Services Authority.

Pursuant to Comissão de Valores Mobiliários Rule 483, Citi is required to disclose whether a Citi related company or business has a commercial relationship with the subject company. Considering that Citi operates multiple businesses in more than 100 countries around the world, it is likely that Citi has a commercial relationship with the subject company.

Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to CIRA's Products can be found at https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures.

Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations.

The Product may have been distributed simultaneously, in multiple formats, to the Firm's worldwide institutional and retail customers. The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would not be permitted.

Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. The Product does not purport to identify the nature of the specific market or other risks associated with a particular transaction. Advice in the Product is general and should not be construed as personal advice given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs. Prior to acquiring any financial product, it is the client's responsibility to obtain the relevant offer document for the product and consider it before making a decision as to whether to purchase the product. With the exception of our product that is made available only to Qualified Institutional Buyers (QIBs), CIRA concurrently disseminates its research via proprietary and non-proprietary electronic distribution platforms. Periodically, individual CIRA analysts may also opt to circulate research posted on such platforms to one or more clients by email. Such email distribution is discretionary and is done only after the research has been disseminated via the aforementioned distribution channels. CIRA simultaneously distributes product that is limited to QIBs only through email distribution.

The level and types of services provided by CIRA analysts to clients may vary depending on various factors such as the client's individual preferences as to the frequency and manner of receiving communications from analysts, the client's risk profile and investment focus and perspective (e.g. market-wide, sector specific, long term, short-term etc.), the size and scope of the overall client relationship with Citi and legal and regulatory constraints.

CIRA product may source data from dataCentral. dataCentral is a CIRA proprietary database, which includes Citi estimates, data from company reports and feeds from Reuters and Datastream.

© 2012 Citigroup Global Markets Inc. Citi Investment Research & Analysis is a division of Citigroup Global Markets Inc. Citi and Citi with Arc Design are trademarks and service marks of Citigroup Inc. and its affiliates and are used and registered throughout the world. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure of this report (the "Product"), including, but not limited to, redistribution of the Product by electronic mail, posting of the Product on a website or page, and/or providing to a third party a link to the Product, is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient to any third party. Where included in this report, MSCI sourced information is the exclusive property of Morgan Stanley Capital International Inc. (MSCI). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, disseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI, Morgan Stanley Capital International and the MSCI indexes are services marks of MSCI and its affiliates. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to website material of the Firm, the Firm takes no responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST
